Counterpoint: Cholesteryl ester transfer protein antagonism by drugs - A poor choice

Clinical Chemistry

Volumn 56, Issue 10, 2010, Pages 1550-1553

  Sirtori, Cesare R ^a   Mombelli, Giuliana ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; TORCETRAPIB; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE;

ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; REVIEW; TREATMENT FAILURE; ANIMAL; BLOOD; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG POTENTIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; NOTE; RISK;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; HEPTANOIC ACIDS; HUMANS; POLYMORPHISM, GENETIC; PYRROLES; QUINOLINES; RISK;

EID: 77957727800     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.147389     Document Type: Review

References (19)

1. Franceschini G, Werba JP, Calabresi L. Drug control of reverse cholesterol transport. Pharmacol Ther 1994;61:289-324. (Pubitemid 24207702)
2. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, et al. Increased high-density lipoprotein levels caused by a common cholesterylester transfer protein gene mutation. N Engl J Med 1990;323:1234-8. (Pubitemid 20366528)
3. Hirano K, Yamashita S, Kuga Y, Sakai N, Nozaki S, Kihara S, et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 1995;15:1849-56.
4. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol and possible decreased risk of ischemic heart disease. The Copenhagen City Heart Study. Circulation 2000;102:2197-203. (Pubitemid 30225270)
5. Fricke-Schmidt R, Johannsen TH, Schou J, Nordestgaard BG, Tybjaerg-Hansen A. Cholesteryl ester transfer protein genotype predicts anti-atherogenic lipid profile and decreased risk of ischemic heart disease, ischemic cerebrovascular disease, and death not attributable to HDL cholesterol alone. Circulation 2009;120(Suppl 2):S1175. Abstract 5919.
6. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der Steege G, et al., on behalf of the PREVEND Study Group. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006;91:3382-8.
7. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000;20:1323-9. (Pubitemid 30262934)
8. Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E, et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010;121:366-74.
9. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7. (Pubitemid 30469005)
10. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 2002;103:587-94. (Pubitemid 36005711)
11. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005;25:1057-64. (Pubitemid 40627855)
12. Sirtori CR, Mombelli G. Viability of developing CETP inhibitors. Cardiovasc Ther 2008;26:135-46.
13. Cazita PM, Barbeiro DF, Moretti AI, Quintao EC, Soriano FG. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock 2008;30:590-5.
14. Clark RW, Cunningham D, Cong Y, Subashi TA, Tkalcevic GT, Lloyd DB, et al. Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection. J Lipid Res 2010;51:967-74.
15. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, Sirtori CR. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 1989;9:462-9.
16. Arakawa R, Tsujita M, Iwamoto N, Ito-Ohsumi C, Lu R, Wu CA, et al. Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis. J Lipid Res 2009;50:2299-305.
17. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-6. (Pubitemid 34158156)
18. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis 2009;207:16-23.
19. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008;118:2506-14.